Alaunos Therapeutics Inc
TCRT
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.25M
Close$
$0.50
76.8% downside
Current Fair Value
76.8% downsideOvervalued by 76.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.25 Million |
|---|---|
| Enterprise Value | $4.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.2 |
| Beta | -1.06 |
| Outstanding Shares | 1,948,357 |
Return
| Return on Equity | -319.02% |
|---|---|
| Return on Assets | -218.22% |
| Return on Invested Capital | -323.29% |
Valuation & Multiples
| P/E Ratio | -1.02 |
|---|---|
| PEG | 16.33 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1632.2 |
| Enterprise Value to EBIT | -1.18 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.46%▲ 1.49% |
|---|---|
| Total Invested | $360,538▲ 3.04% |
| Investors Holding | 29▲ 3.00% |
ESG Score
No data
About Alaunos Therapeutics Inc
105 employeesZiopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled int...